Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
INO
$1.56
$-0.05
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Next Earnings
2026-01-11
Beta
1.626
Average Volume
1518356
Market Cap
83600188
Last Dividend
0
CIK
0001055726
ISIN
US45773H4092
CUSIP
45773H201
CEO
Jacqueline E. Shea
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
134
IPO Date
1998-12-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 | I believe Inovio Pharmaceuticals' upside rests almost entirely on INO-3107. The FDA set a standard-review PDUFA for October 30, 2026. INO-3107 targets HPV-6/11 RRP, aiming to reduce repeat surgeries by inducing HPV-specific T-cell responses and addressing the disease's underlying causes. But the FDA questioned INO-3107's accelerated approval. I think this increases the risk of longer timelines with larger confirmatory requirements. | Seeking Alpha | 2026-01-10 09:30:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO | NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-08 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-06 12:45:00 |
| Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Hold” by Analysts | Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO - Get Free Report) have earned an average recommendation of "Hold" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. | Defense World | 2025-12-31 01:48:55 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2025-12-30 16:25:00 |
| FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with RRP. | PRNewsWire | 2025-12-29 08:05:00 |
| INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). | PRNewsWire | 2025-12-19 16:05:00 |
| Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript | Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript | Seeking Alpha | 2025-12-02 10:13:30 |
| INOVIO to Participate in December Investor Conferences | PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Tuesday, December 2 Time: 8:30-8:55 AM ET Format: Fireside Chat Webcast: https://bit.ly/44af19l (live webcast and replay available for 90 days after the event) Oppenheimer Movers in Rare Disease Summit (New York, NY) Date: Thursday, December 11 Time: 12:05-12:25 PM ET Format: Panel - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts Members of INOVIO's management team will also be conducting one-on-one meetings with investors during these conferences. | PRNewsWire | 2025-11-18 08:05:00 |
| Inovio (INO) Upgraded to Buy: Here's Why | Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2025-11-14 13:03:27 |
| Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress | Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash, expects a runway into 2Q26, and announced a $25 million public offering to support operations. Key pipeline progress includes completion of the BLA submission for INO-3107, with hopes for FDA priority review and potential U.S. launch by mid-2026. | Seeking Alpha | 2025-11-12 09:53:12 |
| INOVIO Announces Pricing of $25 Million Public Offering | PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share. | PRNewsWire | 2025-11-11 08:40:00 |
| Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript | Inovio Pharmaceuticals, Inc. ( INO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer Steven Egge - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Felix Ampomah Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. | Seeking Alpha | 2025-11-10 19:31:34 |
| INOVIO Announces Proposed Public Offering | PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. | PRNewsWire | 2025-11-10 18:09:00 |
| INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted Commercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA Results from Phase 1 proof-of-concept trial evaluating INOVIO's next generation DNA-Encoded Monoclonal Antibody (DMAb™) technology published in Nature Medicine PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2025 and provided an update on recent company developments. | PRNewsWire | 2025-11-10 16:05:00 |
| INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults | Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designations; BLA submitted under FDA's Accelerated Approval program Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted PLYMOUTH MEETING, Pa. , Nov. 3, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has completed the rolling submission of its Biologics License Application (BLA) for its DNA immunotherapy candidate INO-3107 for the treatment of RRP in adults. | PRNewsWire | 2025-11-03 08:05:00 |
| INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa. , Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). | PRNewsWire | 2025-10-31 16:53:00 |
| INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025 | PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025. | PRNewsWire | 2025-10-27 08:05:00 |
| INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference | PLYMOUTH MEETING, Pa. , Oct. 23, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference. | PRNewsWire | 2025-10-23 16:05:00 |
| Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine | Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity through week 72 No immune rejection of the DMAbs detected across ~1,000 blood samples Most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug PLYMOUTH MEETING, Pa. , Oct. 21, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced results from a Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19 were published online in Nature Medicine under the title "Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial. | PRNewsWire | 2025-10-21 08:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| SC 13G/A | 2025-12-08 | 2025-12-08 | View Filing |
| SC 13G | 2025-12-05 | 2025-12-05 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G/A | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 424B5 | 2025-07-03 | 2025-07-03 | View Filing |
| 424B5 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G | 2025-04-30 | 2025-04-30 | View Filing |
| SC 13G/A | 2025-04-17 | 2025-04-17 | View Filing |
| ARS | 2025-04-07 | 2025-04-07 | View Filing |
| DEF 14A | 2025-04-07 | 2025-04-07 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13G | 2025-02-10 | 2025-02-10 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| SC 13G/A | 2025-01-30 | 2025-01-30 | View Filing |
| SC 13G | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 8-K | 2024-12-16 | 2024-12-16 | View Filing |
| 424B5 | 2024-12-13 | 2024-12-13 | View Filing |
| 424B5 | 2024-12-12 | 2024-12-12 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 424B5 | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 8-K | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-13 | 2024-05-13 | View Filing |
| 4 | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| SC 13G | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-04-17 | 2024-04-17 | View Filing |
| 424B5 | 2024-04-17 | 2024-04-17 | View Filing |
| ARS | 2024-04-15 | 2024-04-15 | View Filing |
| DEF 14A | 2024-04-11 | 2024-04-11 | View Filing |
| 10-K | 2024-03-06 | 2024-03-06 | View Filing |
| 4 | 2024-02-28 | 2024-02-28 | View Filing |
| 4 | 2024-02-28 | 2024-02-28 | View Filing |
| 4 | 2024-02-28 | 2024-02-28 | View Filing |
| 4 | 2024-02-28 | 2024-02-28 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Quantum Inspired Strategy | 27.60% | 1.01 | 463 | 0.02 | 0.05 | 21.11 |
| Neural Forcast | 26.07% | 1 | 902 | 0.01 | 0.03 | 19.58 |
| Adaptive Wave | 24.43% | 1.98 | 3 | 0.02 | 0.06 | 17.94 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |